Chloroquine for the 2019 novel coronavirus SARS-CoV-2

International Journal of Antimicrobial Agents

Volumn 55, Issue 3, 2020, Pages

  Colson, Philippe ^a,b   Rolain, Jean Marc ^a,b   Raoult, Didier ^a,b  

^a AIX MARSEILLE UNIVERSITY   (France)

^b IHU MÉDITERRANÉE INFECTION   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; HYDROXYCHLOROQUINE; REMDESIVIR; TEICOPLANIN; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2;

ANTIVIRAL ACTIVITY; CHINA; CORONAVIRUS DISEASE 2019; CORONAVIRUS INFECTION; DRUG EFFICACY; DRUG REPOSITIONING; DRUG SAFETY; EC50; EDITORIAL; IN VITRO STUDY; NONHUMAN; PHAGOLYSOSOME; PRIORITY JOURNAL; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; SEVERE ACUTE RESPIRATORY SYNDROME 2; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; VIRUS INHIBITION; VIRUS ISOLATION; VIRUS REPLICATION; ANIMAL; BAT; BETACORONAVIRUS; CORONAVIRINAE; EPIDEMIC; PNEUMONIA;

ANIMALS; BETACORONAVIRUS; CHIROPTERA; CHLOROQUINE; CORONAVIRUS; DISEASE OUTBREAKS; PNEUMONIA; SARS VIRUS;

EID: 85079880333     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2020.105923     Document Type: Editorial

References (16)

1. Mullard, A., Drug repurposing programmes get lift off. Nat Rev Drug Discov 11 (2012), 505–506, 10.1038/nrd3776.
2. Zhou, P., Yang, X.L., Wang, X.G., Hu, B., Zhang, L., Zhang, W., et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 2020 Feb 3, 10.1038/s41586-020-2012-7 [Epub ahead of print].
3. Savarino, A., Di Trani, L., Donatelli, I., Cauda, R., Cassone, A., New insights into the antiviral effects of chloroquine. Lancet Infect Dis 6 (2006), 67–69, 10.1016/S1473-3099(06)70361-9.
4. Rolain, J.M., Colson, P., Raoult, D., Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. Int J Antimicrob Agents 30 (2007), 297–308, 10.1016/j.ijantimicag.2007.05.015.
5. Vincent, M.J., Bergeron, E., Benjannet, S., Erickson, B.R., Rollin, P.E., Ksiazek, T.G., et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J, 2, 2005, 69, 10.1186/1743-422X-2-69.
6. Ksiazek, T.G., Erdman, D., Goldsmith, C.S., Zaki, S.R., Peret, T., Emery, S., et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 348 (2003), 1953–1966, 10.1056/NEJMoa030781.
7. Balzarini, J., Keyaerts, E., Vijgen, L., Egberink, H., De Clercq, E., Van Ranst, M., et al. Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics. Antiviral Res 72 (2006), 20–33, 10.1016/j.antiviral.2006.03.005.
8. Keyaerts, E., Vijgen, L., Maes, P., Neyts, J., Van Ranst, M., In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun 323 (2004), 264–268, 10.1016/j.bbrc.2004.08.085.
9. Barnard, D.L., Day, C.W., Bailey, K., Heiner, M., Montgomery, R., Lauridsen, L., et al. Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice. Antivir Chem Chemother 17 (2006), 275–284, 10.1177/095632020601700505.
10. de Wilde, A.H., Jochmans, D., Posthuma, C.C., Zevenhoven-Dobbe, J.C., van Nieuwkoop, S., Bestebroer, T.M., et al. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother 58 (2014), 4875–4884, 10.1128/AAC.03011-14.
11. Yu, I.T., Qiu, H., Tse, L.A., Wong, T.W., Severe acute respiratory syndrome beyond Amoy Gardens: completing the incomplete legacy. Clin Infect Dis 58 (2014), 683–686, 10.1093/cid/cit797.
12. Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., Xu, M., et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res, 2020 Feb 4, 10.1038/s41422-020-0282-0 [Epub ahead of print].
13. Agostini, M.L., Andres, E.L., Sims, A.C., Graham, R.L., Sheahan, T.P., Lu, X., et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio, 9, 2018, 10.1128/mBio.00221-18 pii: e00221-18.
14. White, N.J., Pukrittayakamee, S., Hien, T.T., Faiz, M.A., Mokuolu, O.A., Dondorp, A.M., Malaria. Lancet 383 (2014), 723–735, 10.1016/S0140-6736(13)60024-0.
15. Al-Bari, M.A., Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases. J Antimicrob Chemother 70 (2015), 1608–1621, 10.1093/jac/dkv018.
16. Lee, S.J., Silverman, E., Bargman, J.M., The role of antimalarial agents in the treatment of SLE and lupus nephritis. Nat Rev Nephrol 7 (2011), 718–729, 10.1038/nrneph.2011.150.